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Letter to the Editor
structures, PD/AG and SAD mainly differ regarding the periaque-
ductal grey as well as occipitotemporal and parietal regions related 
to the ventral object recognition pathway [2] and salience network 
[3]. Those networks might be crucial in SAD due to the high rel-
evance of detecting social cues. 
Fear conditioning serves as a model for the development, main-
tenance and treatment of anxiety disorders via CBT [4]. It involves 
the (pre-)motor cortex, medial prefrontal cortex/anterior cingu-
late cortex, anterior insula, amygdala, hippocampus and thalamus 
[4], which have also been partly identified as pathophysiologi- 
cal correlates of PD/AG [5] and SAD [3], thus indicating shared 
pathogenic pathways. 
The aim of this analysis was to investigate whether CBT spe-
cifically tailored to primary PD/AG also targets clinical and neu-
rofunctional correlates of secondary SAD. 
We here present a secondary analysis of data originally col-
lected by the German research network “Panic-Net” on CBT in 
PD/AG [6]. Two hundred and forty-two completer data sets were 
available (PD/AG+SAD: n = 100), including 42 with pre- and 
posttreatment functional magnetic resonance imaging (fMRI) 
assessments (PD/AG+SAD: n = 14). Adults with primary PD/AG 
according to DSM-IV-TR criteria were included. Patients suffer-
ing from other current comorbidities such as SAD – except for 
psychotic, bipolar or borderline personality disorder and alcohol 
dependence – were included, unless they were the primary diag-
nosis. Patients received a manualized 12-session CBT treatment 
targeting primary PD/AG [6]. The Structured Interview Guide 
for the Hamilton Anxiety Rating Scale (SIGH-A) [7] was the pri-
mary outcome. The Brief Symptom Inventory subscale Interper-
sonal Sensitivity (BSI-Sens [8]) served as a proxy measure of SAD 
(see online suppl. Methods and Tables S1 and S2 for detailed in-
formation; see www.karger.com/doi/10.159/000493756, for all 
online suppl. material). We applied a previously validated [6] dif-
Clinicians frequently treat patients suffering from more than 
one mental disorder. As they have to choose which disorder to 
treat first, knowledge on generalization effects or even comorbid-
ity-associated obstacles should guide the clinician’s decision. Pa-
tients with panic disorder (PD) and agoraphobia (AG) often suffer 
from other mental disorders, e.g. social anxiety disorder (SAD) [1]. 
Nevertheless, evidence is missing whether cognitive-behavioral 
therapy (CBT) for PD/AG generalizes to SAD or whether comor-
bid SAD impedes the treatment of primary PD/AG. 
Neurally, both disorders exhibit substantial neurofunctional 
overlap within the defensive system network. Beyond overlapping 
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Fig. 1. Brain activation clusters differentially activated during fear 
conditioning and extinction in patients with panic disorder and 
agoraphobia with (PD/AG+SAD) or without comorbid social anx-
iety disorder (PD/AG-SAD) prior to and after exposure-based 
cognitive-behavioral therapy. The corresponding bar graphs show 
β-values for the peak voxels extracted from a 5-mm sphere over 
the time course (pre/post) as well as group differences and differ-
ences regarding the conditioned stimuli. Error bars indicate the 
standard error of the mean. L, left; R, right; CS+, stimulus associ-
ated with the unconditioned stimulus; CS–, CS not associated with 
the unconditioned stimulus; AU, arbitrary units. MNI coordinates 
in parentheses; p < 0.005 (uncorr.) with a minimum cluster size of 
142 contiguous voxels, indicating to correct for multiple compari-
sons at p < 0.05 (Monte Carlo simulation). * p < 0.05, ** p < 0.01, *** p < 0.001.
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ferential fear conditioning task comprising familiarization, ac-
quisition and extinction with colored geometric stimuli as con-
ditioned stimuli (CS) and an aversive white noise (individually 
adapted: 70–110 dB) as unconditioned stimulus. fMRI images 
were acquired with 3-T scanners. Age, Anxiety Sensitivity Index, 
Clinical global Impression Scale and Beck Depression Inventory 
scores were entered as covariates (see online suppl. Table S2). In 
line with the primary fMRI outcome paper [6], an individual vox-
el type I error at p < 0.005 with a cluster extent of 142 contiguous 
resampled voxels indicated significant effects corrected for mul-
tiple comparisons at p < 0.05 (Monte Carlo simulation) [9]. 
β-Values were extracted for repeated measures ANOVA and post 
hoc t contrasts from corresponding main and interaction effects 
(see suppl. Methods for details on fMRI data acquisition and 
analysis). 
In the clinical and the fMRI sample, we observed a significant 
reduction of SIGH-A scores within both groups (see online suppl. 
Tables S3, S4 and Fig. S1). Moreover, CBT effectively reduced SAD 
symptoms in PD/AG+SAD patients to the level of PD/AG-SAD-
patients (see online suppl. Fig. S1).
On the neurofunctional level (Fig. 1 and online suppl. Tables 
S5 and S6), PD/AG+SAD patients exhibited enhanced activation 
in the bilateral superior temporal pole, left middle temporal gyrus 
(MTG), left inferior frontal operculum (IFO), left insula and right 
anterior cingulate cortex. Furthermore, PD/AG+SAD patients 
showed a stronger activation upon the CS+ within the left MTG 
and the right hippocampus compared to PD/AG-SAD patients 
particularly during early acquisition.
Prior to treatment, PD/AG+SAD patients showed a higher ac-
tivation than PD/AG-SAD patients within the left superior tempo-
ral pole (acquisition) and left IFO (extinction), which was signifi-
cantly reduced after treatment. Activations were reduced even be-
low the level of PD/AG-SAD patients within the left IFO and left 
amygdala. 
A significant group × time × CS interaction during early acqui-
sition within the left MTG and right hippocampus indicated a sig-
nificantly stronger activation upon the CS+ among PD/AG+SAD 
patients at baseline. Prior to treatment, only PD/AG+SAD patients 
differentiated between CS+ and CS–. After treatment, MTG acti-
vation upon the CS+ was reduced significantly in PD/AG+SAD 
patients to the level of PD/AG-SAD patients. Moreover, activation 
upon the CS– significantly increased among PD/AG+SAD pa-
tients within the hippocampus. No significant differences or acti-
vation changes within the MTG or the hippocampus were ob-
served among PD/AG-SAD patients. 
In this study, we were able to highlight the relevance of comor-
bidity in PD/AG. Clinically, PD/AG-specific treatment is equally 
effective in patients with or without SAD comorbidity. It further-
more bears potential to generalize to secondary SAD symptom-
atology, thus favoring the idea of a general mechanism that may 
foster the transfer of fear-inhibitory learning. Neurally, results 
demonstrate a signature associated with secondary SAD, encom-
passing two functional systems: first, this signature extends 
throughout the ventral object recognition pathway, which is re-
lated to the recognition of social cues and thus SAD symptomatol-
ogy; second, comorbid SAD further amplifies the activation of de-
fensive system structures (e.g., hippocampus and IFO) possibly 
indicating stronger conditionability as a function of comorbidity. 
Both systems were effectively targeted by CBT, resulting in attenu-
ated activation patterns to the level of PD/AG-SAD patients. 
Major limitations are a missing primary SAD group, the inclu-
sion of other comorbidities besides SAD and the use of the BSI-
Sens as proxy measure of SAD symptomatology. Monte Carlo sim-
ulations have recently been criticized as they may facilitate false-
positive results. Therefore, the results are preliminary and 
crucially need replication in a larger sample.
Our results warrant further basic and clinical research as they 
indicate that exposure-based CBT is a powerful approach for treat-
ing PD/AG accompanied by SAD and leads to a symptom reduc-
tion extending to the neural level in both disorders even though 
only PD/AG is specifically targeted. Future studies should investi-
gate comorbid conditions more in depth to identify common path-
ways of change that possibly follow overarching functional do-
mains as laid out by the Research Domain Criteria framework [10]. 
Identifying these may help to develop time-efficient treatments 
particularly for patients suffering from more than one anxiety dis-
order.
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